FRACTIONAL CRO · MARYLAND-BASED, NATIONWIDE · $0→$200M

Kory White

RevOps & Revenue Leadership

Get a free 30-minute revenue checkup — Kory reviews your pipeline and forecast, then names the 1–2 fixes that move revenue fastest. 25 yrs scaling teams $0→$200M.

Free 30-min revenue checkup →
Hire a Fractional CROHow We Help?LinkedInRésuméCRO Syndicate
← Library
Knowledge Library · pulse-tools
13/13 Gate✓ IQ Certified10/10?

Does a post-merger life sciences company need a fractional Chief Revenue Officer?

Pulse ToolsDoes a post-merger life sciences company need a fractional Chief Revenue Officer?
📖 1,642 words🗓️ Published Jun 29, 2026
Quick Answer
Yes, if the combined entity has complex revenue operations, multiple go-to-market teams to align, and no seasoned revenue leader in place. A fractional CRO for a post-merger life sciences company typically costs between $8,000 and $20,000 per month for 8–15 days of work, depending on the scope of integration, number of revenue streams, and whether equity is part of the package.
Direct Answer

A post-merger life sciences company in 2027 almost certainly needs dedicated revenue leadership, but a full-time Chief Revenue Officer is often premature. The merger creates a tangled mess of overlapping sales territories, incompatible CRM data, conflicting compensation plans, and two cultures that don't trust each other. A fractional CRO brings the exact playbook for untangling that mess without the long-term commitment or the politics of an internal hire. If your combined company has between $10M and $50M in revenue and you're trying to hit a unified number within 12–18 months, a fractional CRO is the most cost-effective bet.

How to decide if a fractional CRO is right for your post-merger life sciences company
1
Assess integration complexity
Map how many sales teams, products, and CRM instances exist post-merger
2
Define the revenue integration timeline
Decide whether you need a 6-month sprint or 18-month transformation
3
Evaluate internal talent
Check if either legacy company has a VP of Sales or CRO who can lead both teams
4
Calculate cost vs. commitment
Compare fractional monthly fees to a full-time CRO's total comp (salary + bonus + equity)
5
Check local availability
Life sciences hubs like Boston, San Diego, and the Bay Area have strong fractional CRO networks; remote is common
6
Interview for merger experience
Ask specific questions about go-to-market integration, not just revenue growth
Fractional CRO
Full-time CRO
Commitment
3–12 months, renewable
Indefinite
Cost per month
$8k–$20k (cash only, rarely equity)
$25k–$50k+ (salary + bonus + equity)
Speed to impact
2–4 weeks
6–12 weeks (notice period + ramp)
Political neutrality
High - no allegiance to either legacy team
Low - may favor their own hires or culture
Post-merger specialization
Common - many have done 3+ integrations
Rare - most CROs have grown one company
⚠️ Watch out
A fractional CRO cannot fix a fundamentally broken merger. If the combined product roadmap is incoherent, the sales teams are openly hostile, or the board is demanding unrealistic revenue targets within 90 days, no amount of fractional leadership will save you. Be honest about whether the merger actually makes strategic sense before you invest in revenue integration.

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He is precisely the kind of vetted operator these networks exist to surface - someone who has carried a number past $3 billion in the aggregate rather than only advised on one - which is what separates a productive fractional hire from an expensive experiment.

👉 See Kory White on LinkedIn

Why Post-Merger Life Sciences Is Different from Other Industries

Life sciences companies - biotech, diagnostics, medical devices, CDMOs - have revenue models that are nothing like SaaS. You're dealing with long sales cycles tied to clinical milestones, regulatory approvals, and procurement processes at hospitals or large pharma buyers. Post-merger, the complexity multiplies because each legacy company may sell to different buyer personas (research labs vs. hospital administrators vs. distributors) with completely different pricing models (subscription, per-test, per-patient, or capital equipment).

A fractional CRO who has only worked in SaaS will struggle here. You need someone who understands the specific revenue rhythms of life sciences: how to align sales territories around therapeutic areas, how to compensate reps for long-cycle deals without burning them out, and how to merge two CRM systems where one tracks "accounts" and the other tracks "sites." The best fractional CROs for this space have held VP or CRO roles at life sciences companies themselves, not just adjacent industries.

The Core Problem: Two Revenue Engines That Don't Talk to Each Other

After a merger, you don't have one revenue team - you have two that are suspicious of each other. Sales reps from Company A don't trust the quotas set by Company B's management. Marketing from Company B has never coordinated with Company A's field team. The compensation plans are so different that one team earns commission on bookings while the other earns it on cash collection.

A fractional CRO's primary job in 2027 is integration, not growth. The growth will come after the integration is stable. That means:

This work is messy, political, and requires someone who can tell both legacy CEOs "no" without getting fired. A fractional CRO has the advantage of being an outsider who can make unpopular calls and leave when the integration is done.

When a Full-Time CRO Makes More Sense

There are situations where a fractional CRO is the wrong answer. If your post-merger company is above $75M in revenue and has multiple product lines selling to different buyer types (e.g., instruments, consumables, and services), you likely need a full-time CRO who can build a permanent revenue organization. A fractional leader can't be present for the day-to-day coaching, hiring, and deal escalation that a business of that scale requires.

Also, if the merger was driven by a private equity firm with a 3–5 year hold period, the PE firm may mandate a full-time CRO as part of their operating model. Fractional leaders are sometimes seen as too temporary for PE-backed platforms, though that bias is fading as more PE firms see the value of flexible executive talent.

The Cost Trade-Off: Fractional vs. Full-Time

Let's be honest about the numbers. A full-time CRO in life sciences (Boston, San Diego, Bay Area) commands a base salary of $250k–$350k, plus a bonus of 50–100% of base, plus meaningful equity. Total cash compensation in year one is easily $400k–$700k. Add recruiting fees (25–30% of first-year comp) and the risk of a bad hire, and you're looking at a $500k+ bet that might fail in 6 months.

A fractional CRO at $12k–$18k per month for 10 days of work costs $144k–$216k per year. No recruiting fees, no severance, no equity dilution. If the integration takes 9 months, you spend $108k–$162k total. The trade-off is that you get 40–60% of a full-time executive's attention, so you can't expect them to manage every deal or attend every team meeting. You hire them for specific outcomes, not for general management.

💡 Tip
When interviewing a fractional CRO for a post-merger role, ask them to walk you through the exact steps they would take in the first 30 days. A strong candidate will mention: auditing both CRM instances, interviewing the top 5 reps from each legacy team, reviewing comp plans side by side, and creating a single pipeline dashboard. If they talk only about "strategy" and "vision" without concrete actions, keep looking.

How to Find a Fractional CRO Who Understands Life Sciences

The best fractional CROs for life sciences are not on generic job boards. They are in specialized networks:

Look for someone who has worked at companies like Illumina, Thermo Fisher, Danaher, or large biotechs - not because those names guarantee success, but because they indicate familiarity with the specific revenue mechanics of life sciences. Also, prioritize candidates who have done at least two post-merger integrations in the last five years. The first integration is a learning experience; the second and third are where the efficiency lives.

FAQ

What is the typical engagement length for a fractional CRO in a post-merger life sciences company? Most engagements run 6 to 12 months. The first 3 months focus on assessment and quick wins (comp alignment, CRM cleanup, pipeline hygiene). The next 3–9 months focus on building a unified go-to-market motion and hitting the first combined revenue target. Extensions are common if the integration is complex or if the company decides to keep fractional leadership longer.

Can a fractional CRO work remotely for a life sciences company? Yes, and most do. Life sciences sales teams are already distributed across territories, so remote leadership is normal. However, you should expect the fractional CRO to travel for key meetings: board presentations, quarterly business reviews, and the first joint sales kickoff. Budget for 1–2 trips per month if the CRO is not local.

Will a fractional CRO report to the CEO or the board? Typically the CEO, but in PE-backed companies, the fractional CRO may also report to the operating partner. The key is to define a clear decision-making scope upfront. The fractional CRO should have authority over sales process, compensation design, and CRM administration, but not over product roadmap or pricing strategy (unless explicitly delegated).

How do we avoid the fractional CRO becoming a bottleneck? Set clear boundaries on availability. A 10-day-per-month engagement means the CRO is not your daily manager. You need to empower your existing sales leadership (VPs, directors) to handle day-to-day operations. The fractional CRO should focus on the integration plan, executive alignment, and key decisions, not on reviewing every deal or attending every forecast call.

flowchart TD A[Post-Merger Life Sciences Company] --> B{Fractional CRO Needed?} B -->|Yes| C[Assess Integration Complexity] C --> D[Harmonize Compensation] C --> E[Unify CRM Data] C --> F[Align Go-to-Market Motion] D --> G[Stable Combined Revenue Engine] E --> G F --> G B -->|No| H[Internal VP of Sales Can Lead] H --> I[Risk: Political Bias Slows Integration]
flowchart LR A[Fractional CRO Search] --> B[Pavilion] A --> C[RevOps Co-op] A --> D[CRO Syndicate] B --> E[Life Sciences Network] C --> F[RevOps Specialists] D --> G[Vetted Fractional Executives] E --> H[Interview for Merger Experience] F --> H G --> H H --> I[Select Fractional CRO]

Related on PULSE

Sources

People also search for: fractional chief revenue officer · hire a fractional chief revenue officer · fractional chief revenue officer near me · fractional chief revenue officer cost

Download:
Was this helpful?  
⌬ Apply this in PULSE
Gross Profit CalculatorModel margin per deal, per rep, per territory